Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for July 2011
July 1, 2011
- FDA Drug Safety Communication: Children born to mothers who took Valproate products while pregnant may have impaired cognitive development
- Diamyd Medical: Quarterly Report III 10/11
- Lilly Unwavering on Independence
- Merck to Close Inspire Facility
- Baxter 2010 Sustainability Report Details Progress Toward Priorities and Goals
- Shire Files Lawsuits Against Sandoz and Amneal for Infringement of VYVANSE (lisdexamfetamine dimesylate) Patents
July 5, 2011
- Chantix May Cause More Heart Attacks Than Previously Thought
- Pfizer Affirms Chantix/Champix As Important Treatment Option for Smokers Wanting to Quit
- Almirall Strengthens Its German Business With Two New Products: Sativex and Actikerall
- Biogen Idec Researchers Identify Novel Approach for Promoting Remyelination and Inhibiting Autoimmune Activation as Potential Therapeutic Option for Treatment of Multiple Sclerosis
- Drug Companies Eye US Entry After FDA Checks
- 'Skills Gap' Leaves Firms Without Worker Pipeline
- Merck & Co's Two Senior Officials Vacate Posts in India
- Roche Returns Development and Marketing Rights of SGLT2 Inhibitor ?CSG452? to Chugai
July 6, 2011
- Rib-X Pharmaceuticals and Sanofi Sign a Research Collaboration Agreement on Novel Classes of Antibiotics
- Some Pediatricians Taking Stand for Vaccine Program
- Medical Giant Helps Tackle Drugs Cheats ; Olympics
- Cytrx Gets Rare Disease Status for Cancer Therapy
- Clinical Data Due for Small Biotechs
- Pharmasset Climbs As Analyst Raises Target
- GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
- ImpactRx Measures How Patient Brand Requests Drive Physician Treatment Decisions
July 7, 2011
- Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE (lisdexamfetamine dimesylate) Patents
- Addex Announces Corporate Reorganization and Restructuring Initiative to Strengthen Its Leadership Position in Allosteric Modulation-Based Drug Discovery and Development
- Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement for an Investigational Immuno-Oncology Biologic
- Russian Police Raid Teva's Moscow Office
- Antitrust: Commission Welcomes Improved Market Entry for Lung Disease Treatments
- You Are What You Tweet: Tracking Public Health Trends With Twitter
July 8, 2011
- FDA MedWatch - Nulojix (belatacept): Risk Evaluation and Mitigation Strategy (REMS) - Increased Risk of PTLD and PML
- Sanofi Provides Multaq Phase IIIb PALLAS Trial Update
- Pfizer and Astellas Announce the Transfer of Distribution Rightsfor Caduet Combination Tablets to Astellas
- Onconova and SymBio Complete License Agreement for Rigosertib, a Phase III Stage Multi-Kinase Inhibitor for Cancer
- Watson Confirms Favorable Appeals Court Decision in Mucinex Patent Suit
- Online Medical Collaboration Network (MCN) Introduces SeeDocNow, a New Free iPhone Application for Instant and Live Medical Consultation. Your Next Doctor Visit is Going To Be On The iPhone.
July 11, 2011
- Valeant Pharmaceuticals Agrees to Acquire Dermik
- Watson and Antares Announce Exclusive License Agreement for Antares' Oxybutynin Gel Product (Anturol®)
- Nevada State Judge Denies Roche and Genentech's Motions to Dismiss PDL BioPharma's Complaint
- Trade Groups Gain Feds' Ear
- Bayer Healthcare - European Patent Office Decides on Yasmin Patent Challenge
- Teva Faces 2 Key Court Hearings Today
- Space Shuttle Cargo Includes Mice in Amgen Test
- Teva Settles With Merck Over Cholesterol Drugs
- Withdrawal from the Market of Pioglitazone-Containing Products:Actos and Competact in France
- GlaxoSmithKline Receives FDA Approval for Boostrix to Help Prevent Whooping Cough in Adults 65 Years and Older
July 12, 2011
- Ipsen and Institut de cancérologie Gustave Roussy enter into a partnership agreement
- More AIDS Patients May Get Cheaper Drugs
- Half of Patients with Parkinson's Disease and Psychosis Treated With Antipsychotic Agents, Including Drugs that May Worsen Parkinson Symptoms
- Gilead Expands Access Program for Medications in Developing World
- European Medicines Agency Reviews Cardiovascular Risk of Multaq
- License Agreement for the Sale of Pirfenidone (Pirespa) in South Korea With Ildong Pharmaceutical
- Renewal of Agreement Between Ipsen and the Salk Institute Supports Cutting-Edge Research
- Zogenix and Durect Announce Development and License Agreement for Antipsychotic Product Candidate
- Medical Mystery: How Did the Drug Company Get His Name
July 13, 2011
- Eisai Enters into Comprehensive Chinese Marketing Agreement Concerning Breast Cancer and Parkinson's Disease Treatments
- Bayer Pouring Millions Into South Charleston Facilities
- Penn Professor Accuses Colleagues of Research Misconduct
- Obama Should Remove Top Advisor on Bioethics
- Seattle Genetics Shares Fall on FDA Drug Review
- Roche Sues Teva Over Anti-Nausea Drug
- AHA Survey: Drug Shortages Delay Patient Treatment
July 14, 2011
- Van Hollen Announces Settlement With UCB, Inc. to Resolve Health Care Fraud Allegations
- Teva Completes Acquisition of Taiyo, the Third Largest Generics Company in Japan
- Scientists Explore Alternative to Antibiotics
- Lilly and Argonne National Laboratory Announce $2 Million Upgrade to Lilly's Beamline Capabilities
- Astellas Files Lawsuit Against Sandoz For Patent Litigation In Canada
- European Medicines Agency Responds To Criticism 0f Staff Member
- EMD Serono, Inc. Announces Appointment of James Hoyes as President
- Roche Announces Thomas Schinecker as New President of 454 Life Sciences
July 15, 2011
- Vical, Astellas Ink Licensing Deal on Vaccine
- ICON Acquires Firecrest Clinical
- Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
- Crestor and Zocor Drugs Linked to Muscle Degeneration, Rhabdomyolysis
July 18, 2011
- FDA: Diabetes Drug May up Cancer Risk
- Shionogi Inc. Signs Agreement to Expand Its Portfolio with Acquisition of Nine Marketed Products from Victory Pharma, Inc.
- Labopharm Announces Further Workforce Reduction
- Ahead of the Bell: Report Says PPD Explores Sale
- Amgen Resolves G-CSF Patent Litigation With Teva
- FDA Approves Vaccines for the 2011-2012 Influenza Season
- PPD Comments on Recent Stock Market Developments
July 19, 2011
- Novartis Delivers Strong Financial Results and Four Major Approvals in Second Quarter of 2011
- Daiichi Sankyo Launches LIXIANA (edoxaban), a Direct Oral Factor Xa Inhibitor, in Japan for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
- Rib-X Pharmaceuticals Receives $9 Million Milestone Payment from Sanofi in the RX-04 Collaboration
- Forest Laboratories, Inc. Reports Fiscal Year First Quarter 2012 Earnings Per Share of $0.90 Including a $0.14 Charge for a New Product Licensing Fee
- Johnson & Johnson Reports 2011 Second-Quarter Results
- Allergan, Inc. to Acquire Privately Held Dermatologic Company, Vicept Therapeutics
- FDA Outlines Oversight of Mobile Medical Applications
- Roche Acquires mtm Laboratories AG, Expanding Offering in Cervical Cancer Testing
- CEL-SCI Corporation and Teva Pharmaceuticals Expand Licensing Agreement
July 20, 2011
- AMAG Pharmaceuticals and Allos Therapeutics Agree to Merge to Strengthen Commercial Portfolio and Achieve Cost Synergies
- Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C
- Abbott Reports 11 Percent Ongoing Earnings-Per-Share Growth in Second Quarter; Raises 2011 EPS Guidance Range
- Pfizer to Acquire Icagen
- Government Must Investigate Human Experiments That Test a Dangerous Novartis Drug
- Israeli Generic Drug-Maker Teva to Close Plant in Mirabel, Que.
- SuperGen Completes Acquisition of Astex Therapeutics
- Kendall Law Group Investigates Allos Therapeutics, Inc.
July 21, 2011
- Actelion announces Half Year 2011 financial results
- Baxter's Second Quarter Financial Results Exceed Guidance; Company Raises Full-Year Financial Outlook
- Express Scripts and Medco Health Solutions Sign Definitive Merger Agreement; Medco Shareholders to Receive $29.1 Billion
- Lilly Reports Second-Quarter 2011 Results
- Pradaxa (dabigatran etexilate mesylate) Capsules Now on Formulary at Nation's Top Heart Hospitals
- Roche on Track Full Year Earnings Outlook Increased
- Idera Reports Clinical Hold on Proposed Phase 2 Clinical Trial of IMO-3100
- FDA MedWatch - Oral Osteoporosis Drugs (bisphosphonates): Drug Safety Communication - Potential Increased Risk of Esophageal Cancer
- European Medicines Agency Recommends Restricting Use of Pandemrix
- Merck and Simcere Sign Agreement to Establish Pioneering China Joint Venture
July 22, 2011
- FDA Drug Safety Communication: Ongoing safety review of oral osteoporosis drugs (bisphosphonates) and potential increased risk of esophageal cancer
- Flu Jab Linked to Sleeping Disorder
- FDA Drug Safety Communication: Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events
- Bristol-Myers Squibb to Acquire Amira Pharmaceuticals
- Health Canada Reviews Heart Safety of Drug Used for Abnormal Heart Rhythm
- European Medicines Agency Recommends Revised Labeling and Guidance for Pioglitazone-Containing Products
- GlaxoSmithKline European Regulatory Update on Pandemrix
- European Medicines Agency Recommends New Contra-Indications and Warnings for Pioglitazone to Reduce Small Increased Risk of Bladder Cancer
- FDA MedWatch - Multaq (dronedarone): Drug Safety Communication - Increased Risk of Death or Serious Cardiovascular Events
- New Senior Executives Appointed at Sanofi:
- Lilly: Federal Cuts Could Hurt Drug Makers
- HHS Announces Proposal to Improve Rules Protecting Human Research Subjects
July 25, 2011
- Drug Prices to Plummet in Wave of Expiring Patents
- Chantix (varenicline): Label Change - Risk of Certain Cardiovascular Adverse Events
- Watson Confirms JALYN Patent Challenge
- European Medicines Agency Recommends Revised Labeling and Guidance for Pioglitazone-Containing Products
- Decision Resources Group Acquires PharmaStrat
July 26, 2011
- Watson Second Quarter 2011 Net Revenue Exceeds $1 Billion; Non-GAAP EPS of $1.01
- Merck to Acquire Rights to Vernakalant i.v. in Canada, Mexico and the United States from Astellas
- Lawsuit Says Dialysis Giants DaVita, Inc. and Gambro Healthcare, Inc. Sought Fraudulent Reimbursements for Hundreds of Millions of Dollars for Wasted Drugs, According to Atlanta Lawyers Lin Wood and Marlan Wilbanks
- Daiichi Gets FDA Approval for Liquid Diabetes Drug
- GSK delivers strong Q2 performance with underlying sales growth* of 5%, increased pipeline visibility and dividend of 16p, up 7%
- Lilly Among Corporate Leaders in Charitable Giving
- CSL Limited Signs Commercial License Agreement with Selexis SA
July 27, 2011
- FDA Drug Safety Communication: Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications
- FDA Drug Safety Communication: Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications
- FDA Notifies Pharmaceutical Companies that Studies Conducted by Cetero Research May Require Reevaluation
- Q2/2011: Merck Total Revenues Increase by 16% to EUR 2.6 Billion
- FDA MedWatch - Zyvox (linezolid): Drug Safety Communication - Serious CNS Reactions Possible When Given to Patients Taking Certain Psychiatric Medications
- Hospira Reports Second-Quarter 2011 Results
- Teva Reports Second Quarter 2011 Results
- Mylan's Second Quarter 2011 Adjusted Diluted EPS Increases 41% to $0.52
- Elan Reports Second Quarter and First Half 2011 Financial Results
- Glaxo Pledges to Boost UK Manufacturing and Research
- Glaxo CEO Predicts Drop in R&D As Industry Contracts
- US, Europe Sales Boost Gilead Sciences 2Q Profit
- R&B Legend Natalie Cole Joins Rock Legend Gregg Allman, Merck and the American Liver Foundation to Turn Up the Volume Around Hep C
- Global Market for Anti-Infective Drugs Anticipated to Exceed $100 Billion by 2015: PharmaLive Special Report
- Meda responds to article in The Wall Street Journal
- Lilly Launches Physician Payment Registry
- Successful Discoveries & Technological Advancements Drive Device Sectors: PharmaLive Special Report
July 28, 2011
- Bristol-Myers Squibb Delivers Excellent Second Quarter with Global New Product Approvals, Important Clinical Data and Strong Financial Results
- Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time
- Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms
- Baxter Establishes Baxter Ventures to Invest in Early-Stage Therapies
- Teva CEO: Competition Not Harming Copaxone
- AstraZeneca PLC - Second Quarter and Half Year Results 2011
- 79% of Seniors Oppose Deficit-Linked Medicare Cuts
- Bayer continues positive momentum
- Bristol-Myers Squibb's Profit Falls, Still Tops Estimates
- Bayer Achieves Strong First-Half Sales in North America
- McNeil Consumer Healthcare Announces Plans for New Dosing Instructions for Tylenol Products
- Icagen Stockholders Contest Proposed Acquisition Price by Pfizer in Letter to Board
- PCMA: Study Credits PBM Tools with Reducing Prescription Drug Spending Growth
- Teva Announces Launch of Camrese the Authorized Generic of Seasonique
- Watson Launches Generic Seasonique
- Monthly Roundup - July 2011
July 29, 2011
- Unapproved Emergency Birth Control Medicine Possibly in U.S. Distribution May be Ineffective and Unsafe
- Deceptive Trade Suit Against Drug Makers to Proceed
- Merck Announces Second Quarter 2011 Financial Results
- Amgen's Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
- Cetero Research Responds to FDA Untitled Letter
- Merck Completes Patient Enrollment in SETTLE, a Phase III Pivotal Clinical Trial of Safinamide in Advanced Parkinson?s Disease
- Amgen's Profit Falls in Second Quarter
- Pozen Reports Second-Quarter Loss
- U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent
